List of Excipients in Branded Drug CYCLOPENTOLATE HYDROCHLORIDE

Generic Drugs Containing CYCLOPENTOLATE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Akorn	cyclopentolate hydrochloride	17478-100	BENZALKONIUM CHLORIDE
Akorn	cyclopentolate hydrochloride	17478-100	BORIC ACID
Akorn	cyclopentolate hydrochloride	17478-100	EDETATE DISODIUM
Akorn	cyclopentolate hydrochloride	17478-100	HYDROCHLORIC ACID
Akorn	cyclopentolate hydrochloride	17478-100	POTASSIUM CHLORIDE
Akorn	cyclopentolate hydrochloride	17478-100	SODIUM CARBONATE
Akorn	cyclopentolate hydrochloride	17478-100	WATER

What are the Most Frequently-Used Excipients in CYCLOPENTOLATE HYDROCHLORIDE?

# Of NDCs	Excipient
7	BENZALKONIUM CHLORIDE
7	BORIC ACID
7	EDETATE DISODIUM
7	HYDROCHLORIC ACID
7	POTASSIUM CHLORIDE
7	SODIUM CARBONATE
7	WATER

Cyclopentolate Hydrochloride Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 24, 2026

Cyclopentolate hydrochloride is an established ophthalmic antimuscarinic used for mydriasis and cycloplegia. The active ingredient has limited remaining exclusivity value, so commercial differentiation depends on excipient selection, preservative strategy, pediatric usability, packaging, supply reliability, and regulatory execution. The strongest opportunities are preservative-free unit-dose products, low-irritation formulations, pediatric presentation improvements, and combination ophthalmic products.

What is cyclopentolate hydrochloride used for?

Cyclopentolate hydrochloride is an ophthalmic anticholinergic that blocks muscarinic receptors in the iris sphincter and ciliary muscle. It is used primarily for:

• Cycloplegic refraction
• Diagnostic pupil dilation
• Ophthalmic examinations
• Pediatric eye-care procedures

Commercial ophthalmic strengths generally include 0.5% and 1.0% solutions. The 1.0% concentration is commonly used in adults and older children, while 0.5% is often selected for younger pediatric patients or patients at higher risk of systemic anticholinergic effects.

The drug is administered topically to the eye, but systemic exposure can occur through the nasolacrimal duct. Pediatric patients are particularly relevant because systemic absorption may produce central nervous system or cardiovascular effects. Product design therefore must address both ocular tolerability and dose control. [1]

What is the FDA regulatory status of cyclopentolate hydrochloride?

Cyclopentolate hydrochloride ophthalmic solution is an established prescription drug with an FDA-approved pathway based on a recognized active pharmaceutical ingredient and conventional ophthalmic dosage form.

Regulatory attribute	Cyclopentolate hydrochloride ophthalmic solution
Therapeutic class	Ophthalmic antimuscarinic
Primary use	Mydriasis and cycloplegia
Common strengths	0.5% and 1.0%
Dosage form	Sterile ophthalmic solution
Regulatory category	Prescription ophthalmic drug
Reference product history	Cyclogyl and equivalent products
Likely generic pathway	ANDA for pharmaceutically equivalent solution
Alternative pathway	505(b)(2) for materially differentiated formulation or delivery system
Biologic status	Not applicable
Biosimilar risk	None
Primary regulatory risks	Sterility, preservative performance, stability, extractables and leachables, container closure integrity

An ANDA is generally the most efficient route for a conventional solution that matches the reference product in active ingredient, strength, dosage form, route, and relevant quality attributes. A 505(b)(2) application becomes more relevant when the product uses a novel excipient system, preservative-free multidose technology, modified delivery device, or a clinically differentiated dosing regimen.

A formulation change does not automatically create a 505(b)(2) opportunity. The regulatory benefit must be tied to a distinct product profile, such as reduced ocular toxicity, improved pediatric administration, longer in-use stability, or a delivery system that materially changes dose control.

What excipients are used in cyclopentolate hydrochloride ophthalmic solutions?

Conventional cyclopentolate hydrochloride ophthalmic solutions use a relatively simple aqueous system. Public product labeling identifies excipients such as boric acid, potassium chloride, purified water, and pH-adjusting agents. Some commercial products also use benzalkonium chloride as a preservative. Exact excipient composition varies by manufacturer and presentation. [2,3]

The main excipient functions are:

Excipient function	Typical formulation objective
Vehicle	Dissolve cyclopentolate hydrochloride and deliver a sterile ocular dose
Buffer	Maintain pH during shelf life and after repeated use
Tonicity agent	Reduce stinging and improve ocular comfort
Preservative	Control microbial growth in multidose containers
Chelator	Improve preservative performance or reduce metal-catalyzed degradation
Surfactant or wetting agent	Improve drop formation and surface spreading
pH adjuster	Set the final formulation pH
Container-closure system	Preserve sterility and control delivered volume

Cyclopentolate hydrochloride is a salt form with favorable aqueous solubility. That reduces the need for complex solubilizers, cosolvents, or surfactant systems. A simple formulation has a commercial advantage because it reduces manufacturing complexity and the number of quality attributes requiring control.

How should the excipient strategy be designed?

The optimal strategy depends on the target market rather than on solubility alone. A conventional preserved solution is the lowest-cost option, while a preservative-free or improved-delivery product offers greater differentiation.

Conventional multidose formulation

A conventional multidose product may use:

• Purified water
• Boric acid or another ophthalmically accepted buffer
• Potassium chloride or another tonicity adjuster
• Hydrochloric acid or sodium hydroxide for pH adjustment
• Benzalkonium chloride or another preservative

This approach supports an ANDA-style product and is suitable for routine diagnostic use. Its principal weaknesses are limited differentiation and potential ocular-surface irritation associated with chronic or repeated exposure to preservatives.

Preservative-free unit-dose formulation

A preservative-free unit-dose product eliminates preservative exposure and may be attractive for:

• Pediatric ophthalmology
• Patients with ocular-surface disease
• High-frequency clinical use
• Ophthalmology practices seeking lower preservative burden
• Hospitals and ambulatory surgery centers with unit-dose administration protocols

The disadvantages are higher packaging cost, greater material consumption, more complex filling operations, and possible waste from single-use containers. The commercial case is strongest where safety, tolerability, and infection-control benefits justify a premium.

Preservative-free multidose formulation

A preservative-free multidose container is a more technically demanding opportunity. The package must prevent microbial ingress through valve design, one-way flow control, or another validated system. Development priorities include:

• Container-closure integrity
• Microbial ingress resistance
• Delivered-dose consistency
• Priming and re-priming behavior
• Tip contamination control
• In-use stability
• Compatibility with cyclopentolate hydrochloride solution

This format may create stronger product differentiation than a simple unit-dose vial, but device development and regulatory documentation are more extensive.

Low-irritation formulation

A low-irritation product would optimize:

• pH
• Osmolality
• Buffer capacity
• Preservative concentration
• Drop size
• Surfactant concentration
• Ionic strength

The objective is not merely to match physiological pH. Excessive buffering can increase discomfort or alter ocular residence behavior. The product should balance chemical stability, preservative efficacy, comfort, and compatibility with the container.

What are the main excipient risks?

Benzalkonium chloride exposure

Benzalkonium chloride is effective and widely used in ophthalmic products, but repeated exposure may damage the ocular surface or exacerbate irritation in susceptible patients. This concern is commercially relevant even when the product is used for short diagnostic procedures, because ophthalmology clinics increasingly distinguish preserved from preservative-free products.

A BAK-containing product remains commercially viable when price and standard clinic workflow dominate purchasing. A preservative-free product has a clearer value proposition in pediatric and specialty settings.

Preservative efficacy

Removing BAK does not eliminate the need to demonstrate microbiological protection for a multidose product. The manufacturer must validate the preservative system under applicable pharmacopoeial testing and establish in-use stability. A weak preservative strategy can create regulatory delay, recall risk, or institutional purchasing barriers.

pH and osmolality

Cyclopentolate formulations may be adjusted to a pH that balances active stability and ocular tolerability. Excessive pH adjustment can increase stinging. Inadequate buffering can allow drift during storage or after repeated opening.

Osmolality also affects patient comfort. A formulation that is chemically stable but significantly hypertonic may be less attractive in pediatric practice.

Container interaction

Potential issues include:

• Adsorption of cyclopentolate to polymer surfaces
• Extractables from low-cost plastic containers
• Leachables from elastomer components
• Sorption of preservatives into packaging
• Changes in drop size over shelf life
• Closure deformation during shipping

These risks are especially important for low-volume unit-dose systems and preservative-free multidose devices.

Microbiological contamination

Ophthalmic solutions must meet stringent sterility requirements. The commercial product must demonstrate a robust sterile manufacturing process, validated container closure, and appropriate in-use protection. Packaging design can be as important as the liquid formulation.

What patents protect cyclopentolate hydrochloride products?

Cyclopentolate hydrochloride is an old active ingredient, and the core composition-of-matter patent position is no longer commercially significant. The current competitive landscape is therefore driven by formulation, packaging, device, manufacturing, and combination-product rights rather than by active-ingredient exclusivity.

IP category	Commercial relevance
Cyclopentolate composition of matter	No meaningful current exclusivity expected
Conventional ophthalmic solution	Generally vulnerable to generic competition
Preservative system	Potentially protectable if novel and non-obvious
Preservative-free multidose device	Potentially meaningful device and formulation rights
Unit-dose packaging	Usually limited protection unless structurally novel
Pediatric dosing system	Potential opportunity through device or method claims
Cyclopentolate-phenylephrine combination	Possible formulation and method-of-use rights
Manufacturing process	Relevant where it improves sterility, stability, or yield
Container-closure system	Potentially valuable if it controls contamination or dose delivery

Patent value is likely to reside in narrow claims covering a specific preservative-free architecture, a novel drop-delivery system, a stable concentration range, or a combination formulation. Broad claims covering cyclopentolate hydrochloride in a conventional aqueous ophthalmic solution would face substantial validity and prior-art challenges.

What is the Orange Book status of cyclopentolate hydrochloride?

The Orange Book is relevant for identifying listed reference products, approved dosage forms, therapeutic-equivalence information, and any patent or exclusivity information submitted for listed products. For an established generic ophthalmic solution, the practical expectation is limited or no active patent protection that would materially delay an ANDA.

Because Orange Book listings can change by edition and product status, patent conclusions should be tied to the applicable FDA edition and the specific reference-listed drug. The key commercial implication is that a conventional cyclopentolate hydrochloride solution is unlikely to benefit from a substantial Orange Book exclusivity barrier.

For a differentiated product, the manufacturer should assess whether any formulation or device patents are eligible for listing. A patent that protects only a nonessential device component may have limited impact on ANDA timing or substitution.

When does cyclopentolate hydrochloride lose exclusivity?

Cyclopentolate hydrochloride lost its primary active-ingredient exclusivity decades ago. The product is therefore exposed to generic competition, subject to current manufacturing capacity, FDA approval status, and commercial supply.

The relevant exclusivity questions are now:

1. Whether an individual product has unexpired formulation or device patents.
2. Whether an applicant can file an ANDA using a pharmaceutically equivalent solution.
3. Whether any pediatric or clinical exclusivity applies to a specific product.
4. Whether shortages or manufacturing withdrawals reduce effective competition.
5. Whether a new product obtains 3-year clinical investigation exclusivity through a 505(b)(2) application.

A newly approved differentiated formulation could obtain limited regulatory exclusivity if it meets applicable FDA requirements, but that would protect the approved product or approved change rather than restore exclusivity to cyclopentolate hydrochloride as an active ingredient.

Are there Paragraph IV challenges involving cyclopentolate hydrochloride?

Paragraph IV litigation is less likely to be commercially important for a conventional cyclopentolate hydrochloride solution because the active ingredient and basic dosage form are mature. A Paragraph IV certification could arise if an applicant targets a listed product with an unexpired formulation, device, or method-of-use patent.

The likely litigation targets would be:

• Preservative-free multidose technology
• Combination ophthalmic formulations
• Specific delivery devices
• Narrow stability claims
• Pediatric administration systems
• Method-of-use claims covering a particular diagnostic protocol

For a standard 0.5% or 1.0% aqueous solution, the main barriers are normally regulatory quality, manufacturing scale, and commercial access rather than patent litigation.

Which companies are challenging the cyclopentolate market?

The market is primarily served by generic ophthalmic manufacturers and branded ophthalmology companies. Competitive participation may include:

• Manufacturers of cyclopentolate hydrochloride ophthalmic solution
• Contract development and manufacturing organizations
• Specialty ophthalmology companies
• Hospital-focused sterile ophthalmic suppliers
• Companies selling combination mydriatic products

The most relevant competitive variables are:

Competitive variable	Impact
Wholesale acquisition cost	Determines generic substitution and institutional uptake
Product availability	Important during sterile ophthalmic shortages
Preservative profile	Differentiates pediatric and specialty products
Unit-dose availability	Supports hospital and procedure-center use
Drop-size consistency	Affects dose control and patient experience
Supply reliability	Can outweigh modest price differences
Packaging quality	Influences contamination and waste risk
Regulatory history	Affects procurement confidence

Manufacturing reliability is a material competitive advantage in sterile ophthalmics. A low-cost product that experiences recurring shortages may lose institutional contracts to a higher-priced supplier with dependable supply.

What commercial opportunities exist for cyclopentolate hydrochloride?

Preservative-free pediatric product

This is the clearest formulation opportunity. A single-use 0.5% or 1.0% product could target pediatric ophthalmology, where clinicians may prefer to reduce preservative exposure and improve dose control.

The product could use:

• Blow-fill-seal unit-dose containers
• Low-residual-volume packaging
• Clearly differentiated pediatric labeling
• Tamper-evident secondary packaging
• Reduced drop volume to limit systemic exposure

Low-volume delivery system

A smaller drop may reduce the administered dose while preserving diagnostic effect. This could improve tolerability and reduce waste. The device must produce a consistent drop across viscosity, orientation, temperature, and remaining fill volume.

A low-volume device has stronger commercial potential if supported by comparative data showing equivalent dilation or cycloplegia with lower exposure.

Cyclopentolate-phenylephrine combination

Combination products can simplify diagnostic workflows by combining parasympatholytic and sympathomimetic mydriatic activity. The commercial opportunity depends on:

• Compatible pH and stability
• Absence of precipitation
• Preservative compatibility
• Comparable onset and duration
• Appropriate pediatric dosing
• Differentiated clinical or workflow benefit

A combination product may qualify for a 505(b)(2) strategy if the formulation or clinical evidence differs materially from approved individual products.

Institutional unit-dose supply

Hospitals, clinics, and ambulatory facilities may value ready-to-administer unit doses because they reduce cross-contamination risk and simplify inventory control. The product can compete on total procedure cost rather than bottle price alone.

Global-market formulation

A manufacturer can adapt the product for jurisdictions with stronger restrictions or market preferences regarding preservatives. Geographic differentiation may include:

• Preservative-free products for Europe and specialty markets
• Multidose preserved products for price-sensitive markets
• Localized packaging sizes
• Regional sterile manufacturing
• Country-specific pharmacopoeial compliance

The core formulation is relatively simple, but registration and packaging requirements vary by jurisdiction.

How strong is the patent estate for cyclopentolate hydrochloride?

The patent estate for the active ingredient is weak from a current commercial-exclusivity perspective. A new entrant would face greater risk from formulation and execution issues than from blocking patents.

Patent estate factor	Assessment
Active-ingredient protection	Weak or expired
Conventional solution protection	Weak
Preservative-free formulation	Potentially moderate if technically novel
Delivery-device protection	Potentially moderate to strong
Combination product protection	Variable
Manufacturing-process protection	Narrow but potentially useful
Freedom-to-operate risk	Concentrated in device and formulation claims
Litigation exposure	Low for standard solution; higher for differentiated products

A robust freedom-to-operate review should cover U.S., European, Japanese, Chinese, and other target-market patent families. Particular attention should be paid to claims covering ophthalmic multidose containers, preservative-free dispensing systems, drop-size control, and fixed-dose combinations.

What generic launch scenarios exist?

Scenario 1: Conventional ANDA launch

A manufacturer launches a 0.5% or 1.0% preserved ophthalmic solution. This is the lowest-risk and lowest-differentiation route. Price competition is likely to be intense, and market share depends on supply reliability and wholesaler access.

Scenario 2: Preservative-free unit-dose launch

The product commands a premium but incurs higher packaging and distribution costs. Adoption is strongest in pediatrics, hospitals, and practices with preservative-reduction protocols.

Scenario 3: Preservative-free multidose launch

This route offers greater differentiation but requires device validation and stronger regulatory support. It may support a 505(b)(2) strategy and higher pricing if the product demonstrates practical clinical benefits.

Scenario 4: Combination-product launch

A cyclopentolate-phenylephrine product may compete on workflow simplification. Clinical differentiation and combination stability determine commercial viability.

Scenario 5: Supply-led launch

A manufacturer enters a mature market during recurring shortages or competitor withdrawals. The immediate opportunity is reliable supply rather than formulation innovation. This strategy can generate revenue quickly but may be vulnerable once competitors restore production.

What revenue exposure does cyclopentolate hydrochloride create?

Cyclopentolate hydrochloride is unlikely to support large revenue through exclusivity pricing. Revenue potential is instead linked to:

• Number of ophthalmology procedures
• Pediatric examination volume
• Hospital and clinic contracts
• Product availability
• Premium for preservative-free packaging
• Combination-product convenience
• Geographic expansion
• Contract manufacturing utilization

A conventional product has low per-unit value and high price sensitivity. A differentiated product can improve gross margin by increasing willingness to pay, but the addressable market for premium formulations is smaller.

The most defensible commercial position is a portfolio strategy:

1. Low-cost preserved multidose product.
2. Preservative-free unit-dose product.
3. Premium delivery system or combination product.

This approach covers both commodity procurement and specialty ophthalmology demand.

Key Takeaways

• Cyclopentolate hydrochloride is a mature ophthalmic drug with no meaningful active-ingredient exclusivity advantage.
• Conventional 0.5% and 1.0% solutions are primarily generic, price-sensitive products.
• The most attractive excipient strategy is a preservative-free formulation targeted to pediatric and specialty ophthalmology.
• Benzalkonium chloride provides low-cost multidose preservation but creates a differentiation opportunity for preservative-free products.
• Preservative-free multidose delivery systems offer stronger commercial and patent potential than conventional unit-dose packaging.
• Combination products with phenylephrine may support a 505(b)(2) strategy if they provide meaningful formulation or workflow benefits.
• Generic launch risk is driven more by manufacturing reliability, sterility, packaging, and supply continuity than by active-ingredient patent litigation.
• The strongest patent opportunities are narrow claims covering device architecture, preservative-free delivery, drop-volume control, formulation stability, and fixed-dose combinations.

FAQs

Is cyclopentolate hydrochloride still patent protected?

The active ingredient is not expected to have meaningful current composition-of-matter protection. Commercially relevant rights would more likely concern formulations, dispensing devices, combination products, or manufacturing methods.

Is benzalkonium chloride necessary in cyclopentolate eye drops?

No. BAK is used in some multidose products, but preservative-free unit-dose or specialized multidose systems can eliminate or reduce preservative exposure.

Can cyclopentolate hydrochloride be developed as a 505(b)(2) product?

Yes, if the proposed product relies on a meaningful formulation, delivery, combination, or dosing modification that is not adequately covered by a conventional ANDA pathway.

What is the best pediatric formulation opportunity?

A preservative-free 0.5% unit-dose solution with controlled drop volume and low residual fill is the clearest pediatric opportunity. A 1.0% version may be appropriate for selected patients and should have distinct dosing controls.

Is cyclopentolate hydrochloride vulnerable to biosimilar competition?

No. Cyclopentolate hydrochloride is a small-molecule drug. Competition would come from generic ophthalmic products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Cyclopentolate hydrochloride ophthalmic solution prescribing information. FDA-approved product labeling.

2. DailyMed. (2024). Cyclopentolate hydrochloride ophthalmic solution. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ophthalmic preparations and sterility requirements. USP.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. Center for Drug Evaluation and Research.